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Aim To investigate the role of valproic acid (VPA), a class I 
selective histone deacetylase inhibitor, on Michigan Can-
cer Foundation (MCF)-7 breast cancer cells, named and ex-
plore its possible molecular mechanism.
Methods MCF-7 cells were cultured with sodium valproate 
(0. 5-4.0 mmol/L) for 24 h, 48 h, and 72 h in vitro, respective-
ly. The cell viability, apoptosis, and cell cycle were exam-
ined. The activities and protein expressions of caspase-3, 
caspase-8, and caspase-9 were subsequently assayed. Fi-
nally, mRNA and protein expressions of cyclin A, cyclin D1, 
cyclin E, and p21 were analyzed.
Results Sodium valproate suppressed MCF-7 cell growth, 
induced cell apoptosis, and arrested G1 phase in a time- 
and concentration- dependent manner, with the relative 
cell viabilities decreased, cell apoptosis ratios increased, 
and percentage of G1 phase enhanced (P < 0.05). Increased 
activity of caspase-3 and caspase-9, but not caspase-8, and 
increased protein levels were found under sodium val-
proate (2.0 mmol/L, 48h). P21 was up-regulated and cyclin 
D1 was down-regulated at both mRNA and protein levels 
under sodium valproate (2.0 mmol/L, 48h)(P < 0.05), al-
though cyclin E and cyclin A remained changed.
Conclusion These results indicate that VPA can suppress 
the growth of breast cancer MCF-7 cells by inducing apop-
tosis and arresting G1 phase. Intrinsic apoptotic pathway is 
dominant for VPA-induced apoptosis. For G1 phase arrest, 
p21 up-regulation and down-regulation of cyclin D1 may 
be the main molecular mechanism.
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Histone acetylation is dynamically regulated by histone 
acetyltransferase (HAT) and histone deacetylase (HDAC). 
HATs lead to the relaxation of chromatin structures and 
genes transcriptional activation, whereas HDACs are asso-
ciated with chromatin condensation and transcriptional si-
lence (1,2). Alterations in eukaryotic chromatin structures 
caused by acetylation of the core histone N-terminal do-
mains seem to play a central role in the regulation of gene 
transcription. Recent studies have demonstrated the cor-
relation between histone acetylation or deacetylation and 
the genesis and development of some types of tumors 
(3-5). Thus, a new approach to tumor therapy emerged: ac-
tivation of HATs and/or suppression of HDACs.
Histone deacetylase inhibitors (HDACIs), such as sodium 
butyrate (6), apicidin (7), and trichostatin A (8), showed an-
titumor functions, including cell growth inhibition, apop-
tosis induction, tumor cell re-differentiation stimulation, 
and cell cycle arrest induction in G1 phase. Valproic acid 
(VPA), which has been used widely as an anticonvulsant 
for over 20 years and has been well known for its low nox-
ious and prolonged effectiveness (9), was demonstrated as 
a class I selective histone deacetylase inhibitor (10). Multi-
ple antiproliferative effects of VPA resulting from inhibition 
of deacetylase activity were reported in various malignan-
cies, such as human choriocarcinoma (11), thyroid cancer 
(12), hepatic cancer (13), pancreatic cancer (14), breast can-
cer (15), and so on. Various gene expression changes were 
further proved under inhibition of deacetylase activity, in-
cluding up-regulation of multiple cyclin-dependent kinase 
inhibitors and down-regulation of cyclins, nuclear recep-
tors, and p53 (16). A similar study in oral squamous cell car-
cinoma (OSCC) showed that treatment with VPA increased 
the cells distributed in G1 phase and reduced cells in the 
S phase of human tongue squamous cell carcinoma cells 
CAL-27 (17). However, further studies for VPA’s anti-tumor 
function and molecular mechanism are still needed, espe-
cially in breast cancer (18,19), which occurs at high inci-
dence in China.
The aim of the present study was to investigate the role 
of VPA on cultured MCF-7 cells, a typical breast cancer cell 
line, and further explore its possible molecular mechanism, 
particularly in cell apoptosis and cell cycle. Our hypothesis 
was that VPA could inhibit the growth of Michigan Can-
cer Foundation (MCF)-7 by inducing cell apoptosis and 
affecting its cell cycle. Our data showed that VPA sup-
pressed MCF-7 growth, induced apoptosis, and arrested 
G1 phase. Intrinsic apoptotic pathway is dominant in 
VPA-induced apoptosis, and p21 up-regulation and 
down-regulation of cyclin D1 may be the main molecular 
mechanism for G1 phase arrest.
MATERIALS AND METHODS
Reagents
The human breast cancer cell line MCF-7 was obtained 
from the American Type Culture Collection (ATCC). Gibco 
media RPMI 1640 and fetal bovine serum (FBS) were used 
(Invitrogen Co., Carlsbad, CA, USA). Anti-caspase-3, cleaved 
caspase-3, caspase-9, cleaved caspase-9, caspase-8, 
cleaved caspase-8, and p21Waf/cip1 [below as p21) anti-
bodies were obtained from Cell Signaling Technology (Bos-
ton, MA, USA). Anti-cyclin A, cyclin D1, cyclin E, and β-actin 
antibodies were purchased from Santa Cruz Biotechnolo-
gy (Cambridge, UK). Sodium valproate, Cell Counting Kit-8 
(CCK-8), cell apoptosis related reagents, cell cycle detec-
tion reagents, and all other reagents used in the present 
study were all Sigma products (St. Louis, MO, USA).
Cell culture and VPA exposure treatment
MCF-7 cells (1.0 × 105/mL) were cultured in 10% FBS-1640 
medium, with 100 U/mL penicillin and 100 mg streptomy-
cin at 37şC in a humidified atmosphere composed of 95% 
air and 5% CO2. For VPA exposure experiment, cells were 
divided into control and VPA treatment groups. The con-
trol cells were cultured as common and equal amounts 
of phosphate buffered saline (PBS) were added to both 
groups of cells. For VPA treatment groups, different con-
centrations of sodium valproate (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 
3.5, and 4.0 mmol/L) were added into the medium when 
cells reached 70%-80% of confluence, with different expo-
sure times (24 h, 48 h, and 72 h).
The relative cell viability detection under CCK-8
Cells (1.0 × 105/mL) were subcultured in a 96-well cell cul-
ture cluster (Corning Inc., Corning, NY, USA) (100μL/well), 
and each sodium valproate concentration group was set 
to four replicates. CCK-8 (10 μL) was added into each well 
1-4 h before the indicated time points. After 1-4 h of in-
cubation at 37şC, the optical density (OD) values were 
measured at 535 nm using an ELISA reader (Multiskan GO, 
Thermo Scientific, MA, USA). Relative cell viability was cal-
culated according to the following formula:
Relative cell viability (%) = (ODVPA-ODblank) / (ODcontrol-
ODblank) × 100%
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Cell apoptosis analysis based on flow cytometry
Cells were trypsinized and collected at the indicated time 
points as common. As described in the instructions, cells 
(1.0 × 106/group) were suspended in 200 μL binding buf-
fer containing Annexin V/FITC (5 μL) and PI (10 μL) for 15 
minutes at room temperature. Then binding buffer (300 
μL) was added into the tube for further detection by flow 
cytometry (Becton Dickinson, Mountain View, CA, USA). All 
experiments were performed in triplicate.
Assessment of cell cycle
Cells were trypsinized and collected at the indicated time 
points as common. After washing twice by cool PBS, cells 
(1.0 × 106/group) were fixed in 75% frozen ethanol at -20şC 
for 1 hour. Cells were then suspended in 200-500 μL cool 
PBS and, after 20 μL of solution A were added, incubated 
in a water bath at 37 şC for 30 minutes as described in the 
instructions. Then 400 μL of solution B were added, and 
cells were incubated for 30-60 minutes at 4şC, avoiding 
light. Results were analyzed by flow cytometry (FACSCant-
oTM II, Becton Dickinson, NJ, USA). All experiments were 
performed in triplicate. Further cell cycle analysis was con-
ducted based on ModFit LT software.
Reverse transcription-polymerase chain reaction (RT-
PCR) detection
Total RNA was extracted using TRIzol (Invitrogen) as com-
mon (20). Reverse transcription was performed using the 
cDNA synthesis kit in a final volume of 20 μL containing 
3 μg total RNA, and 1 μL Oligo (dt) 18 Primer (0.5 μg/
μL). PCR was conducted according to the instructions of 
Takara TaqTM. The general amplication conditions were 
94°C, 5 minutes; 94°C, 45 seconds; 56 ~ 61.5°C, 45 sec-
onds; 72°C, 45 seconds; 30-35 cycles. Proper volume of 
the amplified product was subjected to 1% agarose gel 
for electrophoresis. All experiments were performed in 
triplicate. The relative optic density (OD) ratio was cal-
culated with the NIH ImageJ software (US National Insti-
tutes of Health, Bethesda, MA, USA) in comparison with 
β-actin. The primers were designed using Primer 5.0 Soft-
ware (Table 1).
Western blot analysis
Total protein was extracted using radio immunoprecipita-
tion assay (RIPA) and was quantified using a BCA kit (Sigma) 
according to the manufacturer’s instructions. Samples (80 
μg of total protein each) were used in Western blot analy-
sis with the first antibodies (caspase-3 1:1000, cleaved cas-
pase-3 1:1000, caspase-9 1:1000, cleaved caspase-9 1:1000, 
caspase-8 1:1000, and cleaved caspase-8 1:1000, cyclin 
A 1:200, cyclin D1 1:200, cyclin E 1:200, p21 1:1000, and 
β-actin 1:2000). The relative OD ratio was calculated with 
the NIH ImageJ software in comparison with β-actin from 
three experiments.
Statistical analysis
Data were presented as mean ± standard deviation (SD). Nor-
mality test was performed using Kolmogorov-Smirnov test. 
One-way analysis of variance (ANOVA) was applied to ana-
lyze these data. For post hoc test, Student-Newman-Keuls 
method was chosen. Pearson correlation analysis was ap-
plied to analyze the correlation between sodium valproate 
exposure time or concentration and the relative cell viabili-
ties of MCF-7. P values less than 0.05 were considered statisti-
cally significant. Statistical calculations were performed using 
the SPSS 16.0 software package (SPSS Inc., Chicago, IL, USA).
RESULTS
VPA exposure inhibited the growth of MCF-7cells
The relative cell viabilities of MCF-7 exposed to sodium 
valproate (0.5 ~ 4.0 mmol/L) for 24 h, 48 h, and 72 h de-
creased in a concentration- and time- dependent manner 
(Figure 1). Taken the relative cell viabilities of control MCF-7 
(sodium valproate 0 mmol/L) as 100%, the relative cell vi-
abilities of MCF-7 under sodium valproate (2.0 mmol/L, 24 
h) were 68.9 ± 6.2% and significantly decreased (P < 0.05). 
For 48 h, the statistical decrease of relative cell viabili-
TAbLE 1. The sequences of primers for reverse transcription-polymerase chain reaction (RT-PCR)
Gene Forward-primer (5′→3′) Reverse-primer (5′→3′)
cyclin A ACCCCTTAAGGATCTTCCTG TCCAGGGTATATCCAGTCTTTCG
cyclin D1 GGATGCTGGAGGTCTGCGAGGAAC GAGAGGAAGCGTGTGAGGCGGTAG
cyclin E ATACAGACCCACAGAGACAG TGCCATCCA CAG AAATACTT
p21 CAGGCGACAGCAGAGGAAGA GGGCGGCCA GGGTATGTAC
β-actin CTCACCCTGAAGTACCCCATCG CTTGCTGATCCA CATCTGCTGG
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ties of MCF-7 could be found from sodium valproate (1.5 
mmol/L), and from sodium valproate (1.0 mmol/L) for 72 
h exposure (P < 0.05). Pearson correlation analysis showed 
that sodium valproate inhibited the growth of MCF-7 cells 
in a concentration- and time-dependent manner (r = 0.825 
and r = 0.416, respectively, P < 0.001 for both).
VPA exposure induced apoptosis of MCF-7 cells under 
flow cytometry
Cell apoptosis was analyzed using flow cytometry after dif-
ferent concentrations of sodium valproate (0.5-4.0 mmol/L) 
were added into the culture medium of MCF-7 cells. In the 
control group, the apoptosis showed no statistical chang-
es with the extension of cell culture time, but different lev-
els of increased apoptosis could be found under sodium 
valproate (Figure 2). For example, the apoptosis in the con-
trol cell group after 24 h, 48 h, and 72 h was 0.83 ± 0.19%, 
1.62 ± 0.35%, and 2.76 ± 0.25%, respectively, whereas the 
apoptosis in the cell group exposed to 2.0 mmol/L so-
dium valproate for 24 h, 48 h, and 72 h was 4.61 ± 0.47%, 
8.32 ± 0.75%, and 11.74 ± 0.95%, respectively (Figure 2A). 
There were also general changes in cell apoptosis under 
different concentrations of sodium valproate for 24 h, 48 h, 
and 72 h (Figure 2B). Pearson correlation analysis showed 
that the apoptosis of MCF-7 was positively correlated with 
sodium valproate concentrations (r = 0.925, P < 0.001).
The G1 phase of cells cycle was arrested under VPA 
exposure
In cultured MCF-7 control cells, G1 phase, S phase, and G2 
phase could be detected successively without obvious 
changes in the ratios of each phase with the extension of cell 
culture time. In sodium valproate-exposed cells, G1 phase 
was arrested at different degrees (Figure 3). The means of 
G1 phase in control cells cultured for 24 h, 48 h, and 72 h 
were 55.3 ± 1.98%, 54.86 ± 2.19%, and 55.44 ± 2.42%, respec-
tively (Figure 3A). In cells exposed to 2.0 mmol/L sodium 
valproate, the median G1 phases after 24 h, 48 h, and 72 h 
were 62.3 ± 4.18%, 64.35 ± 4.57%, and 65.07 ± 3.19%, ie, sta-
tistically higher than that of control (P < 0.05). All changes of 
G1 phase in different sodium valproate-exposed cell groups 
are presented in Figure 3B. For cells exposed to 2.0 mmol/L 
sodium valproate for 24 h and 48 h, statistically significant 
G1 arrest could be observed (P < 0.05), as well as for cells ex-
posed to sodium valproate 1.5 mmol/L (P < 0.05).
FIGURE 1. Valproic acid (VPA) exposure decreased the relative 
cell viabilities of Michigan Cancer Foundation (MCF)-7 in a 
time- and concentration-dependent manner.
FIGURE 2. Cell apoptosis was induced under valproic acid 
(VPA). A. Flow cytometry showed increased apoptosis of Michi-
gan Cancer Foundation (MCF)-7 cells under sodium valproate 
(2.0 mmol/L) for 24 h, 48 h, and 72 h. B. Cell apoptosis ratios 
were increased in a sodium valproate time- and concentra-
tion-dependent manner.
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Caspase-9 and caspase-3 involved in the VPA-induced 
apoptosis
To explore the molecular mechanism involved in VPA-induced 
MCF-7 cells apoptosis, we further investigated the activity 
and protein expressions of caspase-3, caspase-8, and cas-
pase-9 under sodium valproate (2.0 mmol/L, 48 h) based on 
Western blot analysis (Figure 4). Both caspase-3 and cleaved 
caspase-3 (Figures 4A and 4B), caspase-9 and cleaved cas-
pase-9 (Figures 4C and 4D) were significantly up-regulated 
in comparison wiht control (P < 0.05). Taking the relative pro-
tein expressions of control group as 100%, the levels of cas-
pase-3, cleaved caspase-3, caspase-9, and cleaved caspase-9 
were 289.20 ± 24.02%, 297.70 ± 26.75%, 155.34 ± 12.99%, and 
148.49 ± 15.13%, respectively. However, for caspase-8 ex-
pression, no significant change was observed in sodium val-
proate-exposed cell group (Figures 4E and 4F).
mRNA and protein expressions of cell cycle-related 
proteins
The mRNA and protein expression levels of cell cycle-re-
lated proteins, including cyclin A, cyclin D1, cyclin E, and 
FIGURE 3. Cell cycle of Michigan Cancer Foundation (MCF)-7 
was arrested in G1 phase under valproic acid (VPA) exposure. 
A. G1 phase of MCF-7 cells was arrested obviously under 
sodium valproate (2.0 mmol/L) for 24 h, 48 h, and 72 h. B. G1 
phase was arrested in a VPA time- and concentration-depen-
dent manner.
FIGURE 4. The changes of activity and protein expression 
levels of caspase-3, caspase-8, and caspase-9 under sodium 
valproate (2.0 mmol/L, 48 h) were detected. A/B. The changes 
and semi-quantification of caspase-3 and cleaved caspase-3. 
C/D. The changes and semi-quantification of caspase-9 and 
cleaved caspase-9. E/F. The changes and semi-quantification 
of caspase-8 and cleaved caspase-8.
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p21, were analyzed by RT-PCR and Western blot (Figure 5). 
After sodium valproate (2.0 mmol/L, 48 h) treatment, the 
mRNA levels of cyclin D1 decreased and p21 significantly 
increased (P < 0.05), but no significant changes were found 
in cyclin A and cyclin E levels (Figure 5A). For protein ex-
pressions, both cyclin D1 and p21 showed similar changes 
to mRNA, with cyclin D1 being down-regulated and p21 
up-regulated. Cyclin A and cyclin E protein levels showed 
no statistically significant changes (Figures 5B and 5C).
DISCUSSION
The present study showed that VPA, as a class I selective 
histone deacetylase inhibitor, suppressed the growth of 
breast cancer MCF-7 cells, induced apoptosis, and arrest-
ed G1 phase of MCF-7 cells. Intrinsic apoptotic pathway, 
marked as caspase-3 and caspase-9 activity elevation, was 
responsible for VPA-induced apoptosis. Further G1 phase 
arrest, p21 up-regulation, and cyclin D1 down-regulation 
may be the main molecules involved. Our data provided 
the theoretical support for VPA as an antitumor drug in 
breast cancer treatment.
The existing studies provided evidence that a HDAC in-
hibitor could suppress tumor cell proliferation, mainly re-
flected in inhibition of cell growth vigor (21), apoptosis in-
duction (22), cell proliferation cycle arrest (23), and tumor 
cell re-differentiation induction (24). In the present study, 
we explored the role of sodium valproate on breast cancer 
MCF-7 cells, including cell growth, apoptosis, and prolifera-
tion. By applications of different concentrations of sodium 
valproate, we determined the decrease in cell viabilities, 
which suggested the sodium valproate-induced inhibi-
tion of MCF-7 cell growth. Our results showed that 
the cell viability changed in a sodium valproate time- and 
concentration-dependent manner. Additionally, the con-
centration for VPA used in this study was in mM range, 
which is reported to induce hepatotoxicity in cultured 
HepG2 by leading to mitochondrial respiration dysfunc-
tion (25). However, for antitumor function, 0-350 µM con-
centration of the VPA compounds was not reported to 
induce any significant inhibition of MCF-7 cells, which indi-
rectly indicated that the VPA level needed for in MCF-7 cells 
inhibition had to be in mM range (15). The concentration 
used on Hela cells in that study was also in mM range (15). 
Therefore, we inferred that mM level of VPA was needed for 
anti-breast cancer effect. However, this concentration ad-
versely affects the liver function.
For cell apoptosis detection, we used low cytometry to de-
termine the apoptosis ratios based on a series of different 
sodium valproate concentrations. The apoptotic rates ob-
viously increased with increasing sodium valproate doses, 
which confirmed the induction of apoptosis by sodium 
valproate. Further, we explored the molecular mechanism 
involved in sodium valproate-induced apoptosis. Caspase 
was the central component of apoptosis, and caspase cas-
cade was the actuator of apoptosis. Based on its role in 
apoptosis, caspase family was divided into the starting-type 
caspases (such as caspase-8 and caspase 9) and the effect-
type caspases (such as caspase-1, caspase-3, caspase-6, 
and caspase-7). The activation of effect-type caspase acted 
on the respective substrates, inducing apoptosis character-
ized as DNA fragmentation at the nucleosome. According 
to the different component of caspase, cell apoptosis path-
way was divided into extracellular pathway (death receptor 
pathway) and intrinsic apoptotic pathway (mitochondrial 
pathway) (26). Caspase-9 and caspase-3 are two impor-
FIGURE 5. Analysis of cell cycle-related proteins, including cyclin A, cyclin D1, cyclin E, and p21. A. The mRNA levels of cyclin A, cyclin 
D1, cyclin E, and p21. B. The protein expressions of cyclin A, cyclin D1, cyclin E, and p21.C. The semi-quantifications of cyclin A, cyclin 
D1, cyclin E, and p21 protein expression based on Image J software.
355Ma et al: Valproic acid in the growth of breast cancer MCF-7 cells
www.cmj.hr
tant molecular in intrinsic apoptotic pathway and induce 
a series of downstream events during apoptosis, whereas 
caspase-8 is the main molecule involved in the extracel-
lular pathway of apoptosis (27). Thus, we investigated the 
protein expressions of caspase-9, caspase-3, and caspase-8 
during VPA exposure. Our results showed that sodium val-
proate exposure increased caspase-3 and caspase-9 activ-
ity and protein levels, but not caspase-8 activity. This sug-
gested that VPA induced MCF-7 apoptosis mainly through 
the intrinsic apoptotic pathway, but not through the extra-
cellular pathway. Similar findings were reported in anoth-
er study (28). For example, N-hydroxy-4-(4-phenylbutyryl-
amino) benzamide (HTPB), as a novel HDACi, was shown as 
a potential chemotherapeutic agent in lung cancer (29). It 
significantly suppressed lung cancer cells’ proliferation and 
metastases and induced mitochondria-mediated apopto-
sis. A nanoformulation of doxorubicin, Doxil, was believed 
to be active against breast and ovarian cancers (30). Doxil 
exposure of human breast adenocarcinoma cells MCF-7 in-
hibited the activity of HDAC and enhanced apoptosis with 
a significant increase in the loss of mitochondrial mem-
brane potential, DNA fragmentation percentage, and so 
on. Tumor is a cell cycle-related disease and there are many 
regulatory points, with G1/S conversion and G2/M conver-
sion as the most important (31). Tumor cells can smoothly 
pass the G1/S transition and G2/M transition points, which 
results in unlimited cell proliferation. We observed the cell 
cycle distributions under different concentrations of VPA 
and found an increased percentage of cells in G1 phase 
under sodium valproate treatment, which was consistent 
with other reports for human neuroblastoma BE (2)-C cells 
(32) and neuronal cells (33).
Additionally, the transcription and protein expression of 
cyclins could be blocked by cyclin-dependent kinase 
(CDK) inhibitors. Seven types of CDK inhibitors belong-
ing to two families, INK4 and CIP/KIP, have been reported. 
CIP/KIP family, also known as p21 family including p21, 
p27, and p57, could inhibit the role of cyclin-CDK (34). 
Our assay results of the mRNA and protein levels of cyclin 
A, cyclin D1, cyclin E, and p21 showed the up-regulation 
of p21 and down-regulation of cyclin D1, providing some 
clues for the molecular mechanism of VPA to G1 phase 
arrest.
Although some molecular mechanism have been indi-
cated in this study, further research is needed to elucidate 
the many details involved in this possible pathway and the 
underlying molecular mechanism of VPA in breast cancer 
treatment.
In summary, our results indicate that VPA’s effect on MCF-7 
cells includes inhibit cell growth, apoptosis induction, and 
G1 phrase arrest. The mechanism underlying the effect on 
apoptosis induction involves the intracellular pathways (mi-
tochondrial pathway). The mechanism underlying VPA ef-
fect on the cell cycle arrest in G1 phrase induction include 
up-regulation of p21 mRNA and protein expression, which 
can bind CDKs competitively with cyclins, thus reducing 
the cyclin-CDK complexes and inducing G1 phrase arrest. 
Due to down-regulation of cyclin D1, mRNA, and protein 
expression inhibiting cyclin D1-CDK4/CDK6 pathway activ-
ity, cells cannot pass through the G1/S check point.
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